Comparative Effect of Statins and Omega-3 Supplementation on Cardiovascular Events: Meta-Analysis and Network Meta-Analysis of 63 Randomized Controlled Trials Including 264,516 Participants

Autor: Tung Hoang, Jeongseon Kim
Rok vydání: 2020
Předmět:
Male
medicine.medical_specialty
Statin
medicine.drug_class
Atorvastatin
Network Meta-Analysis
Myocardial Infarction
lcsh:TX341-641
Coronary Disease
Cardiovascular event
Disease
030204 cardiovascular system & hematology
Article
law.invention
03 medical and health sciences
0302 clinical medicine
Randomized controlled trial
law
Internal medicine
Fatty Acids
Omega-3
medicine
Humans
cardiovascular diseases
030212 general & internal medicine
Myocardial infarction
Stroke
Aged
Pravastatin
Randomized Controlled Trials as Topic
Nutrition and Dietetics
business.industry
statin
Middle Aged
medicine.disease
Treatment Outcome
Cardiovascular Diseases
Relative risk
Dietary Supplements
Cardiology
Female
Hydroxymethylglutaryl-CoA Reductase Inhibitors
omega-3
business
lcsh:Nutrition. Foods and food supply
Food Science
medicine.drug
Zdroj: Nutrients
Volume 12
Issue 8
Nutrients, Vol 12, Iss 2218, p 2218 (2020)
ISSN: 2072-6643
Popis: Statins and omega-3 supplementation have been recommended for cardiovascular disease prevention, but comparative effects have not been investigated. This study aimed to summarize current evidence of the effect of statins and omega-3 supplementation on cardiovascular events. A meta-analysis and a network meta-analysis of 63 randomized controlled trials were used to calculate pooled relative risks (RRs) and 95% confidence intervals (CIs) for the effects of specific statins and omega-3 supplementation compared with controls. Overall, the statin group showed significant risk reductions in total cardiovascular disease, coronary heart disease, myocardial infarction, and stroke
however, omega-3 supplementation significantly decreased the risks of coronary heart disease and myocardial infarction only, in the comparison with the control group. In comparison with omega-3 supplementation, pravastatin significantly reduced the risks of total cardiovascular disease (RR = 0.81, 95% CI = 0.72&ndash
0.91), coronary heart disease (RR = 0.75, 95% CI = 0.60&ndash
0.94), and myocardial infarction (RR = 0.71, 95% CI = 0.55&ndash
0.94). Risks of total cardiovascular disease, coronary heart disease, myocardial infarction, and stroke in the atorvastatin group were statistically lower than those in the omega-3 group, with RRs (95% CIs) of 0.80 (0.73&ndash
0.88), 0.64 (0.50&ndash
0.82), 0.75 (0.60&ndash
0.93), and 0.81 (0.66&ndash
0.99), respectively. The findings of this study suggest that pravastatin and atorvastatin may be more beneficial than omega-3 supplementation in reducing the risk of total cardiovascular disease, coronary heart disease, and myocardial infarction.
Databáze: OpenAIRE
Externí odkaz: